Forceful efforts to thwart generic drug competition in France have landed multinational pharma firm Sanofi in deep water with the country’s Competition Authority, which has just issued a €40.6m ($52.7m) fine for a smear campaign targeted at the company’s rivals several years ago.
Matthew Bonam, Pharmaceutical Projects Director at AstraZeneca and Tim Davis, chief executive of Exco InTouch discuss their collaboration and the virtues of mHealth in combatting chronic obstructive pulmonary disease.
Prescription drug bulk purchasing agreements can save patients money but could hinder their health outcomes as a result of reduced access to favourable medicines.
John Leonard, Chief Scientific Officer and Vice-President of AbbVie will leave the company in the coming months after twenty years of service, this is just the latest in a series of senior-level R&D departures in the industry, so is this indicative of wider issues within R&D?
The global biosimilar drug market for 2013 will see a 20% growth on last year’s figures to a whopping $2.44 billion, and a new survey indicates that this trend will continue to flourish for the next decade.
In the largest US drug safety settlement to date with a generic drug manufacturer, agreement was reached with Ranxbury USA Inc. for a total payment of US$500 million as well as guilty pleas to multiple felony charges.
Kevin Dolgin speaks to eyeforpharma about pharma's ongoing "crisis" and how improving patient adherence could provide a much needed injection of capital into your bottom line...
An innovative form of 3D technology could eliminate atrial fibrillation caused by the electronic signals in the heart, a major step forward in the treatment of this condition.
Last week in Kenya, GlaxoSmithKline (GSK) and Save the Children announced they will be working together under a formal partnership agreement to support the more rapid development of pediatric pharmaceuticals.
The former chief health strategist at Google, Dr. Roni Zeiger, has launched a new online community for cancer patients and caregivers called Smart Patients.
A new federal report confirms US hospitals are billing wildly varying amounts for the same medical procedures, even within the same locality.
GlaxoSmithKline (GSK) has announced plans to set up a new online system that will enable researchers to access anonymous patient-level data from its clinical trials.
A newly report published by a center-right think tank makes the claim that incoming value-based pricing regulations could lead to difficulties in patients accessing treatment.
A US comprehensive Cancer Centre has discovered that a biological data facility can accelerate recruitment, lower costs, minimise trial size and expedite the testing of medicines during drug development.
The growth of US health care costs has slowed substantially, giving hope to Americans that they may save as much as $770 billion on Medicare spending over the next decade, Harvard economists say. But how long will this cost respite actually last?
India’s Drug Controller General is to increase monitoring of clinical trials following health activists’ pushing for tougher regulations in the Supreme Court, as concerns continue to arise about the safety and integrity of trials across the country.
A three-dimensional ‘heart patch’ is the world’s first synthetically grown human heart muscle, an accurate estimate of traditional human heart tissue that can help test multiple new therapies for affected patients.
Last week, the state of Florida passed legislation allowing for the substitution of biologics with biosimilars alternatives, joining a growing list of states in America to do so.
The European Medicines Agency (EMA) has just released its final advice resulting from the clinical trial advisory groups set up last year. The next step will be the drafting of a policy on proactive access to clinical-trial data ready for consultation mid-2013.
Mark A. Yarborough, PhD, of the Bioethics Program, University of California Davis, has called for patients to see participating in clinical trials as a "civic" duty, proposing “coordinated campaigns to cultivate civic attitudes” about trials.
Two years after receiving Medicaid coverage, the mental health and financial well-being of the beneficiaries fared substantially better than a random uninsured group of the same low income. But clear physical health benefits among scheme recipients have yet to be seen.
The European Commission (EC) has announced the creation of a new €150m fund for brain research, to mark the start of its ‘European Month of the Brain’ initiative. This amount brings total EU investment in brain research since 2007 to over €1.9 billion.
The General Court of the European Union ordered the EMA yesterday (April 30), not to release data based on requests filed under the Freedom of Information Act, at least not until the final ruling.
An analysis of oncology clinical research data uncovers the worrying disparity between incidence and mortality of cancer, and the volume of research conducted in these key areas.
Earlier this week, Big Pharma was accused of profiteering from cancer due to the ‘rip-off’ prices of potentially life-saving treatments. Lucy Brake examines the charges and asks, is this a fair and reasonable accusation?
As new drugs gain their marketing approvals, whether they become new blockbusters remains to be determined by the real-world data, which will inform the decision of whether or not to put the substance on a formulary.
With electronic medical records seeing a greater adoption than at any time in the past 30 years, Brian Wells AVP for Health Technology & Academic Computing at Penn Medicine answers our questions on the viability of widespread adoption.
Recent studies reveal that the use of real-world evidence is gaining traction among physicians worldwide as a primary consideration when recommending appropriate drugs and treatment.
Late last week the United States government confirmed that it would be joining a second civil fraud lawsuit against Novartis, Swiss drug maker for paying doctors and pharmacists in exchange for prescribing its own drugs.
The European Medicines Agency (EMA) has released its list of drugs that are required to include the ‘black triangle’ symbol in their package inserts.
Drawings of stick men, similar to those doodled in school books around the world, could be one way of informing the content of patient adherence and support programmes (PSPs) for osteoporosis patients, according to new research.
Argentina’s pharma market is set to almost triple in value over the next ten years, going from $5.6 billion in 2012 to $15 billion by 2020, according to new research.
The global pharmaceutical industry can expect a growth in earnings this year, as their position in the market remains constant over the next 12 – 18 months.
In a statement released earlier today, Bayer celebrated a net profit increase of 11.5 percent in the first quarter of 2013. But the results fall short of analysts’ estimates as older drugs and plastic unit performances drag down success of innovative health products.
The pharma industry has decades of success in manufacturing and developing life-saving drugs, but should the industry consider the wider effects treatment can have on quality of life? 22 year old cancer patient, Jason Loo says yes.
The New Zealand Innovation Hub has launched a clinical trials portal, a partnership between four of the country's largest District Health Boards, which will inform researchers, clinicians, the industry and the public about on-going clinical trial activity in New Zealand.
With digital adoption no longer an option, but a must, and the growing influence of customers within the pharma industry, your company needs a comprehensive approach that addresses both digital and customer in a complimentary and comprehensive way…
New survey research from Ernst & Young reveals most biotech SMEs are having difficulties demonstrating the value of products under development.
The UK's Office of Fair Trading will investigate GlaxoSmithKline over what the commission suspects were a "pay for delay" deals that allegedly took place in 2001 and 2004.
In a deal worth just under $500 million, GlaxoSmithKline has confirmed they will partner with venture capitalists to kick start up to 10 drug-discovery firms.
Forget China. The cats in Brazil are getting fatter and global drug manufacturers want a share in the spoils. With retail pharma figures reaching $24.8 billion last year, Brazil is beginning to look a lot more attractive than its highly regulated Eastern counterpart.
“Science isn’t advanced enough to justify the costs to develop a [Alzheimer’s] drug,” says Sanofi CEO, Chris Viehbacher.
In one of the America’s biggest corporate takeovers this year, science service provider Thermo Fisher Scientific has brought out the scientific and laboratory equipment maker Life Technologies Corporation for US$13.6 billion.
The White House is under attack. Enraged at President Obama's proposed 2014 budget, drugmakers – brands and generics alike – are speaking out and rallying against a number of potential health plans that include increased rebates in Medicare and a ban on controversial "pay for delay" deals.
After hearing arguments in a case concerning patents on human genes held by Myriad Genetics, the justices drew analogies with chocolate-chip cookies, baseball bats and Amazonian medicinal plants to find a narrow way to rule on a case that may change the course of biomedical research.
America’s biopharmaceutical industry continues to invest significant amounts of time, effort and financial resources into research and development according to the latest report from the Pharmaceutical Research and Manufacturers of America (PhRMA).
Patient-reported outcomes gathered from the internet holds huge potential for the pharma industry and there is increasing regulatory and healthcare provider interest in this data, but just how can we make the most of the mass of information?
Eli Lilly plans to lay off around 1,000 sales reps to reduce costs, after facing competition from generic versions of some of its most profitable meds, according to a person familiar with the matter.
While other industries are looking for what comes next, pharma is still smarting over its slow migration to the digital space. As the market itself is undergoes unprecedented upheaval, it’s time that these firms face their concerns and embrace innovation that can provide some very real returns.
Drug company reps are withholding relevant safety information during sales visits with physicians, according to a recent study by the University of British Colombia. Despite the scant detail provided on related side effects, doctors are still prescribing these drugs to patients.
Ben Steele talks with Eduardo Tchouhadjian, CEO of E. Tchouhadjian & Associates, about how...
NICE have announced the publication a new set of briefings designed to increase uptake of...
30% of pharma executives expect business as usual, as they admit to expecting blockbuster-type...